(CercleFinance.com) – The specialist in contrast products for medical imaging Guerbet is illustrated on the stock market this Friday after returning to growth in the second quarter and confirming its annual objectives.
After a slight decline in activity in the first quarter (-1.3%), the group saw its turnover at constant exchange rates increase by 6.7% in the second quarter, an acceleration in line with the group’s objectives.
For the first half as a whole, sales amounted to €378.6 million, up 2% compared to the first half of 2022. At exchange rates
constant, turnover increased by 2.8%.
In its press release, Guerbet says it is approaching the second half of 2023 with confidence, in particular on the basis of the acceleration of price effects, with growth expected at a faster pace than in the first six months of the year.
For the year as a whole, Guerbet confirms that it is targeting sales growth of more than 5% on a like-for-like basis and at constant exchange rates.
In terms of profitability, the group still anticipates an Ebitda/restated revenue margin rate of around 11%, before a return from 2024 of this margin rate to a level higher than that known in 2021 (14.4%).
Following this publication, the title Guerbet took more than 7% in the middle of the morning on the Paris Stock Exchange, signing one of the strong increases of the Parisian market.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
